Five features of value-based insurance design plans were associated with higher rates of medication adherence

Health Affairs

Volumn 33, Issue 3, 2014, Pages 493-501

  Choudhry, Niteesh K ^a,b   Fisher, Michael A ^a,b   Smith, Benjamin F ^b,c   Brill, Gregory ^b   Girdish, Charmaine ^d   Matlin, Olga S ^d   Brennan, Troyen A ^d   Avorn, Jerry ^a,b   Shrank, William H ^a,b,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Bozeman Deaconess Hospital   (United States)

^d CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ARTICLE; COMORBIDITY; COST; EMPLOYER; HEALTH CARE PLANNING; HEALTH HAZARD; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MEDICATION COMPLIANCE; PHARMACY BENEFIT MANAGER; PRESCRIPTION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TOTAL QUALITY MANAGEMENT; VALUE BASED INSURANCE DESIGN; WELLBEING; CASE MANAGEMENT; CHRONIC DISEASE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE DISPARITY; INSURANCE; MALE; MIDDLE AGED; PURCHASING; STATISTICS AND NUMERICAL DATA; UNITED STATES;

CASE MANAGEMENT; CHRONIC DISEASE; COHORT STUDIES; COST SHARING; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; EVIDENCE-BASED MEDICINE; FEMALE; HEALTHCARE DISPARITIES; HUMANS; HYPERTENSION; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; UNITED STATES; VALUE-BASED PURCHASING;

EID: 84896851877     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2013.0060     Document Type: Article

References (21)

1. Siu AL, Sonnenberg FA, Manning WG, Goldberg GA, Bloomfield ES, Newhouse JP, et al. Inappropriate use of hospitals in a randomized trial of health insurance plans. N Engl J Med. 1986;315(20):1259-66.
2. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1): 61-9.
3. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861-7.
4. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-12.
5. Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-based insurance plus disease management increased medication use and produced savings. Health Aff (Millwood). 2011;30(1):100-8.
6. Gibson TB, Wang S, Kelly E, Brown C, Turner C, Frech-Tamas F, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011;30(1):109-17.
7. Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60(18):1817-24.
8. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-97.
9. Lee JL, Maciejewski ML, Raju SS, Shrank WH, Choudhry NK. Valuebased insurance design: quality improvement but no cost savings. Health Aff (Millwood). 2013;32(7): 1251-7.
10. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood). 2010;29(11): 1988-94.
11. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309.
12. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154(9): 854-64.
13. Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002;55(8): 833-41.
14. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-16.
15. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457-64.
16. Duru OK, Schmittdiel JA, Dyer WT, Parker MM, Uratsu CS, Chan J, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care. 2010;16(1): 33-40.
17. Adams AS, Uratsu C, Dyer W, Magid D, O'Connor P, Beck A, et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA Intern Med. 2013;173(1):54-61.
18. Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, Rosen AB, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3):530-6.
19. Farley JF, Wansink D, Lindquist JH, Parker JC, Maciejewski ML. Medication adherence changes following value-based insurance design. Am J Manag Care. 2012;18(5):265-74.
20. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002-8.
21. Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846-52.